Exploring the applicability of a lesion segmentation method on [
Fluorine-18 fluorothymidine
Non-Hodgkin’s lymphoma
PET/CT
Segmentation
Tumour proliferation volume
Journal
European journal of hybrid imaging
ISSN: 2510-3636
Titre abrégé: Eur J Hybrid Imaging
Pays: England
ID NLM: 101724113
Informations de publication
Date de publication:
25 Dec 2023
25 Dec 2023
Historique:
received:
16
08
2023
accepted:
31
10
2023
medline:
25
12
2023
pubmed:
25
12
2023
entrez:
24
12
2023
Statut:
epublish
Résumé
The determination of the total metabolic tumour volume based on [ We enrolled 23 adult patients with DLBCL confirmed in II-IV stages without nervous system compromise. All patients were scanned using [ Both, liver, and bone marrow can be indistinctly taken as reference tissue. The SUV threshold for a voxel to be considered as belonging to a lesion is expressed in terms of a percentage relative to the patient's uptake in the reference tissue. Found thresholds were: for liver, 62%, 33%, 27%; and for bone marrow, 35%, 21% and 22%, for baseline, iPET and fPET stages, respectively. The relative threshold throughout the treatment has a decreasing tendency along the stages. Based on the results obtained with [
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
The determination of the total metabolic tumour volume based on [
METHODS
METHODS
We enrolled 23 adult patients with DLBCL confirmed in II-IV stages without nervous system compromise. All patients were scanned using [
RESULTS
RESULTS
Both, liver, and bone marrow can be indistinctly taken as reference tissue. The SUV threshold for a voxel to be considered as belonging to a lesion is expressed in terms of a percentage relative to the patient's uptake in the reference tissue. Found thresholds were: for liver, 62%, 33%, 27%; and for bone marrow, 35%, 21% and 22%, for baseline, iPET and fPET stages, respectively. The relative threshold throughout the treatment has a decreasing tendency along the stages.
CONCLUSION
CONCLUSIONS
Based on the results obtained with [
Identifiants
pubmed: 38143262
doi: 10.1186/s41824-023-00184-3
pii: 10.1186/s41824-023-00184-3
doi:
Types de publication
Journal Article
Langues
eng
Pagination
28Informations de copyright
© 2023. The Author(s).
Références
Barrington SF, Meignan M (2019) Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden. J Nucl Med. https://doi.org/10.2967/jnumed.119.227249
doi: 10.2967/jnumed.119.227249
pubmed: 30954945
pmcid: 6681699
Buck AK, Bommer M, Stilgenbauer S et al (2006) Molecular imaging of proliferation in malignant lymphoma. Can Res 66:11055–11061
doi: 10.1158/0008-5472.CAN-06-1955
Capobianco N, Meignan M, Cottereau A-S et al (2021) Deep-learning
doi: 10.2967/jnumed.120.242412
pubmed: 32532925
pmcid: 8679589
Cysouw M, Kramer GM, Frings V et al (2017) Baseline and longitudinal variability of normal tissue uptake values of [18F]-fluorothymidine-PET images. Nucl Med Biol. https://doi.org/10.1016/j.nucmedbio.2017.05.002
doi: 10.1016/j.nucmedbio.2017.05.002
pubmed: 28528264
Ferrández MC, Golla SSV, Eertink JJ et al (2023) An artificial intelligence method using FDG PET to predict treatment outcome in diffuse large B cell lymphoma patients. Sci Rep. https://doi.org/10.1038/s41598-023-40218-1
doi: 10.1038/s41598-023-40218-1
pubmed: 37573446
pmcid: 10423266
Kuker RA, Lehmkuhl D, Kwon D et al (2022) A deep learning-aided automated method for calculating metabolic tumor volume in diffuse large B-cell lymphoma. Cancers. https://doi.org/10.3390/cancers14215221
doi: 10.3390/cancers14215221
pubmed: 36358642
pmcid: 9653575
Martín-Saladich Q, Reynés-Llompart G, Sabaté-Llobera A et al (2020) Comparison of different automatic methods for the delineation of the total metabolic tumor volume in I–II stage Hodgkin lymphoma. Sci Rep. https://doi.org/10.1038/s41598-020-69577-9
doi: 10.1038/s41598-020-69577-9
pubmed: 32724136
pmcid: 7387527
McKinley ET, Ayers GD, Smith RA et al (2013) Limits of [18F]-FLT PET as a biomarker of proliferation in oncology. PLoS ONE. https://doi.org/10.1371/journal.pone.0058938
doi: 10.1371/journal.pone.0058938
pubmed: 24376528
pmcid: 3869703
Mengüç MU, Mehtap Ö, Görür GD et al (2021) The role of interim PET/CT on survival in diffuse large B cell lymphoma. Clin Lymph Myeloma Leuk. https://doi.org/10.1016/j.clml.2021.06.016
doi: 10.1016/j.clml.2021.06.016
Mikhaeel NG, Heymans MW, Eertink JJ et al (2022) Proposed new dynamic prognostic index for diffuse large B-cell lymphoma: international metabolic prognostic index. J Clin Oncol. https://doi.org/10.1200/JCO.21.02063
doi: 10.1200/JCO.21.02063
pubmed: 35357901
pmcid: 9287279
Minamimoto R, Fayad L, Advani R et al (2016) Diffuse large B-cell lymphoma: prospective multicenter comparison of early interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, deauville, and PERCIST criteria for early therapeutic monitoring. Radiology 280:220–229
doi: 10.1148/radiol.2015150689
pubmed: 26854705
Nioche C, Orlhac F, Boughdad S et al (2018) LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-18-0125
doi: 10.1158/0008-5472.CAN-18-0125
pubmed: 29959149
Sasanelli M, Meignan M, Haioun C et al (2014) Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imag. https://doi.org/10.1007/s00259-014-2822-7
doi: 10.1007/s00259-014-2822-7
Schreiber JJ, Anderson PA, Hsu WK (2014) Use of computed tomography for assessing bone mineral density. Neurosurg Focus 37(1):E4
doi: 10.3171/2014.5.FOCUS1483
pubmed: 24981903
Song MK, Chung JS, Shin HJ et al (2012) Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol. https://doi.org/10.1007/s00277-011-1357-2
doi: 10.1007/s00277-011-1357-2
pubmed: 23180437
Spaepen K, Stroobants S, Dupont P et al (2003) [18F]FDG PET monitoring of tumour response to chemotherapy: does [18F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imag. https://doi.org/10.1007/s00259-003-1120-6
doi: 10.1007/s00259-003-1120-6
Valda A, Bastianello M, Casale G et al (2022) [18F]Fluorothymidine preclinical study in non-human primate. Dosimetry and Biodistribution. Medicina (Buenos Aires) 82(2):231–237
Visvikis D, Lambin P, Beuschau Mauridsen K et al (2022) Application of artificial intelligence in nuclear medicine and molecular imaging: a review of current status and future perspectives for clinical translation. Eur J Nucl Med Mol Imag. https://doi.org/10.1007/s00259-022-05891-w
doi: 10.1007/s00259-022-05891-w
Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. https://doi.org/10.2967/jnumed.108.057307
doi: 10.2967/jnumed.108.057307
pubmed: 19837771